The combined supercomputing power of the UK and US national grids has enabled UCL (University College London) scientists to simulate the efficacy of an HIV drug in blocking a key protein used by the lethal virus. The method an early example of the Virtual Physiological Human in action could one day be used to tailor personal drug treatments, for example for HIV patients developing resistance to their drugs.
The study, published online today in the Journal of the American Chemical Society, ran a large number of simulations to predict how strongly the drug saquinavir would bind to three resistant mutants of HIV-1 protease, a protein produced by the virus to propagate itself. These protease mutations are associated with the diseases resistance to saquinavir, an HIV-inhibitor drug.
The study, by Professor Peter Coveney and colleagues at the UCL Department of Chemistry, involved a sequence of simulation steps, performed across several supercomputers on the UKs National Grid Service and the US TeraGrid, which took two weeks and used computational power roughly equivalent to that needed to perform a long-range weather forecast.
The idea behind the Virtual Physiological Human (VPH) is to link networks of computers across the world to simulate the internal workings of the human body. The VPH mainly a research initiative at present allows scientists to simulate the effects of a drug and see what is happening at the organ, tissue, cell and molecular level.
Although nine drugs are currently available to inhibit HIV-1 protease, doctors have no way of matching a drug to the unique profile of the virus as it mutates in each patient. Instead, they prescribe a course of drugs and then test whether these are working by analysing the patients immune response. One of the goals of VPH is for such trial and error methods to eventually be replaced by patient-specific treatments tailored to a persons unique genotype.
Professor Peter C
|Contact: Jenny Gimpel|
University College London